Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer

BJU International

Volumn 100, Issue 6, 2007, Pages 1254-1258

  Walz, Jochen ^b,c   Gallina, Andrea ^b,d   Perrotte, Paul ^b   Jeldres, Claudio ^b   Trinh, Quoc Dien ^b   Hutterer, Georg C ^b   Traumann, Miriam ^b   Ramirez, Alvaro ^b   Shariat, Shahrokh F ^e   McCormack, Michael ^b   Perreault, Jean Paul ^b   Bénard, Francois ^b   Valiquette, Luc ^b   Saad, Fred ^b   Karakiewicz, Pierre I ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Life expectancy; Prediction; Prostate cancer; Radical prostatectomy; Radiotherapy

Indexed keywords

ACCURACY; AGED; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; HUMAN; LIFE EXPECTANCY; MALE; MEDICAL STUDENT; PHYSICIAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RESIDENCY EDUCATION; UROLOGY;

AGED; AGED, 80 AND OVER; CLINICAL COMPETENCE; FOLLOW-UP STUDIES; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 35748939671     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07130.x     Document Type: Article

References (28)

1. Aus G, Abbou CC, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2005 48 : 546 51
2. Scardino P. Update: NCCN prostate cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 2005 3 (Suppl. 1 S29 33
3. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005 293 : 2095 101
4. Ruchlin HS, Pellissier JM. An economic overview of prostate carcinoma. Cancer 2001 92 : 2796 810
5. Statistics Canada. Life tables, Canada, provinces and Territories 2000-2002. Available at http://www.statcan.ca
6. Arias E. United States life tables, 2003. Natl Vital Stat Rep 2006 54 : 1 40
7. Alibhai SM, Naglie G, Nam R, Trachtenberg J, Krahn MD. Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol 2003 21 : 3318 27
8. Chow E, Davis L, Panzarella T et al. Accuracy of survival prediction by palliative radiation oncologists. Int J Radiat Oncol Biol Phys 2005 61 : 870 3
9. Henderson R, Jones M, Stare J. Accuracy of point predictions in survival analysis. Stat Med 2001 20 : 3083 96
10. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987 40 : 373 83
11. Hall WH, Jani AB, Ryu JK, Narayan S, Vijayakumar S. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis 2005 8 : 22 30
12. D'Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Meth Inf Med 1993 32 : 382 7
13. American Cancer Society. Cancer Facts and Figures 2006. American Cancer Society, 2006
14. McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 2004 119 : 174 86
15. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002 38 : 99 166
16. Fowler JE Jr., Terrell FL, Renfroe DL. Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol 1996 156 : 1714 8
17. Tewari A, Johnson CC, Divine G et al. Long-term survival probability in men with clinically localized prostate cancer. a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004 171 : 1513 9
18. Goldner G, Wachter S, Wachter-Gerstner N, Dieckmann K, Potter R. Long-term results in three-dimensional conformal radiotherapy of localized prostate cancer at moderate dose (66 Gy). Strahlenther Onkol 2006 182 : 537 42
19. Krahn MD, Bremner KE, Asaria J et al. The ten-year rule revisited. accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. Urology 2002 60 : 258 63
20. Cowen ME, Halasyamani LK, Kattan MW. Predicting life expectancy in men with clinically localized prostate cancer. J Urol 2006 175 : 99 103
21. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 1996 156 : 127 32
22. Kattan MW. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol 2003 13 : 111 6
23. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995 274 : 626 31
24. Boulos DL, Groome PA, Brundage MD et al. Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent. Cancer 2006 106 : 1804 14
25. Steuber T, Graefen M, Haese A et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol 2006 175 : 939 44
26. Kattan MW, Potters L, Blasko JC et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001 58 : 393 9
27. Specht MC, Kattan MW, Gonen M, Fey J, Van Zee KJ. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol 2005 12 : 654 9
28. Ross PL, Gerigk C, Gonen M et al. Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol 2002 20 : 82 8